The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Value of Mismatch Repair, KRAS , and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Open accessAbstract
Purpose: It is uncertain whether modest benefits from adjuvant chemotherapy in stage II colorectal cancer justify the toxicity, cost, and inconvenience. We investigated the usefulness of defective mismatch repair (dMMR), BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy. Patients and Methods: Immunohistochemistry for dMMR and pyrosequencing for KRAS/BRAF were performed for 1,913 patients randomly assigned between fluorouracil and folinic acid chemotherapy and no chemotherapy in the Quick and Simple and Reliable (QUASAR) trial. Results: Twenty-six percent of 695 right-sided colon, 3% of 685 left-sided colon, and 1% of 407 rectal tumors were dMMR. Similarly, 17% of right colon, 2% of left colon, and 2% of rectal tumors were BRAF mutant. KRAS mutant tumors were more evenly distributed: 40% right colon, 28% left colon, and 36% rectal tumors. Recurrence rate for dMMR tumors was half that for MMR-proficient tumors (11% [25 of 218] v 26% [438 of 1,695] recurred; risk ratio [RR], 0.53; 95% CI, 0.40 to 0.70; P < .001). Risk of recurrence was also significantly higher for KRAS mutant than KRAS wild-type tumors (28% [150 of 542] v 21% [219 of 1,041]; RR, 1.40; 95% CI, 1.12 to 1.74; P = .002) but did not differ significantly between BRAF mutant and wild-type tumors (P = .36). No marker predicted benefit from chemotherapy with efficacy not differing significantly by MMR, KRAS, or BRAF status. The prognostic value of MMR and KRAS was similar in the presence and absence of chemotherapy. Conclusion: MMR assays identify patients with a low risk of recurrence. KRAS mutational analysis provides useful additional risk stratification to guide use of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
Jass, J. R. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02549.x · Cited by 1,384
Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
Grady, W. M., & Carethers, J. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.076 · Cited by 960
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Self-citationGenetic susceptibility to non-polyposis colorectal cancer
Lynch, H. T., & de la Chapelle, A. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.11.801 · Cited by 814
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., Giovannucci, E. L., & Fuchs, C. S. (2009) · Gut · doi:10.1136/gut.2008.155473 · Cited by 777
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Genetic prognostic and predictive markers in colorectal cancer
Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., & Kerr, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2645 · Cited by 705
Self-citationSargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5362 · Cited by 666
Richman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560
Self-citationBRAF Mutation in Metastatic Colorectal Cancer
Tol, J., Nagtegaal, I. D., & Punt, C. J. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904160 · Cited by 445
Deng, G., Bell, I., Crawley, S., Gum, J., Terdiman, J. P., Allen, B. A., Truta, B., Sleisenger, M. H., & Kim, Y. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1118-3 · Cited by 409
Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
Bertagnolli, M. M., Niedzwiecki, D., Compton, C. C., Hahn, H. P., Hall, M., Damas, B., Jewell, S. D., Mayer, R. J., Goldberg, R. M., Saltz, L. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2071 · Cited by 364
Triple-negative/basal-like breast cancer: review
Rakha, E. A., & Ellis, I. O. (2009) · Pathology · doi:10.1080/00313020802563510 · Cited by 281
Braun, M. S., Richman, S. D., Quirke, P., Daly, C., Adlard, J. W., Elliott, F., Barrett, J. H., Selby, P., Meade, A. M., Stephens, R. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5580 · Cited by 280
Self-citationPetersen, V. C., Baxter, K. J., Love, S. B., & Shepherd, N. A. (2002) · Gut · doi:10.1136/gut.51.1.65 · Cited by 273
DNA mismatch repair and cancer
Peltomäki, P. (2001) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00058-2 · Cited by 223
Lanza, G., Gafà, R., Santini, A., Maestri, I., Guerzoni, L., & Cavazzini, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2433 · Cited by 210
Quirke, P., & Morris, E. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02543.x · Cited by 209
Self-citationHeinemann, V., Stintzing, S., Kirchner, T., Boeck, S., & Jung, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 203
Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J., Balaguer, F., Sempere, L., Xicola, R. M., Bujanda, L., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.016 · Cited by 197
Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., Young, M.-A., McArthur, G., Boussioutas, A., & Dobrovic, A. (2007) · Familial Cancer · doi:10.1007/s10689-007-9124-1 · Cited by 165
Morris, E. J. A., Maughan, N., Forman, D., & Quirke, P. (2007) · Gut · doi:10.1136/gut.2006.116830 · Cited by 136
Self-citationIshikawa, T., Fujita, T., Suzuki, Y., Okabe, S., Yuasa, Y., Iwai, T., & Kawakami, Y. (2003) · PubMed · Cited by 117
p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer
Bouzourène, H., Gervaz, P., Cerottini, J., Benhattar, J., Chaubert, P., Saraga, E. P., Pampallona, S., Bosman, F. T., & Givel, J. C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00036-8 · Cited by 117
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. M. (2008) · AACR Education book · doi:10.1158/aacr.edb-ccr-06-1554 · Cited by 99
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Loriot, Y., Mordant, P., Deutsch, É., Olaussen, K. A., & Soria, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.106 · Cited by 93
Søreide, K., Nedrebø, B. S., Søreide, J. A., et al. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0255-4 · Cited by 88
Marshall, J. L., Haller, D. G., de Gramont, A., Höchster, H. S., Lenz, H., Ajani, J. A., & Goldberg, R. M. (2007) · PubMed · Cited by 55
Eveno, C., Nemeth, J., Soliman, H. R., et al. (2010) · Archives of Surgery · doi:10.1001/archsurg.2009.224 · Cited by 53
Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified
Ward, R. L., Turner, J., Williams, R., Pekarsky, B. A. K., Packham, D., Velickovic, M., Meagher, A. P., O'Connor, T. W., & Hawkins, N. J. (2005) · The Journal of Pathology · doi:10.1002/path.1851 · Cited by 53
Management of colorectal cancer
Melville, A., Sheldon, T., Gray, R. G., & Sowden, A. J. (1998) · BMJ Quality & Safety · doi:10.1136/qshc.7.2.103 · Cited by 45
Self-citationAlter, E., Phelip, J., Guilhot, J., Matysiak, M. J., Vermorel, M., & Roblin, X. (2007) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282e1c5b7 · Cited by 9
Cited by
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Self-citationCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Petrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P., Passalacqua, R., Sgroi, G., & Barni, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4227 · Cited by 729
André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683
Metadata
- Authors
- Hutchins, G., Southward, K., Handley, K., Magill, L., Beaumont, C., Stahlschmidt, J., Richman, S., Chambers, P., Seymour, M., Kerr, D., Gray, R., & Quirke, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-04-01
- Volume
- 29
- Issue
- 10
- Pages
- 1261-1270
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171235660
- Cited by
- 681
- References
- 48
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.